We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 344 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

99% less funds holding

Funds holding: 354 → 5 (-349)

99.54% less ownership

Funds ownership: 99.58% → 0.04% (-100%)

100% less capital invested

Capital invested by funds: $8.24B → $2.58M (-$8.24B)

100% less funds holding in top 10

Funds holding in top 10: 29 → 0 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 344

Holders
5
Holders Change
-349
Holders Change %
-98.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-29
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
344
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$2.06K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$822M
2
BlackRock
BlackRock
New York
-$784M
3
PCM
Pentwater Capital Management
Florida
-$500M
4
State Street
State Street
Massachusetts
-$286M
5
UBS Group
UBS Group
Switzerland
-$278M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
201
Sagefield Capital
Texas
– -$1.23M -9,600 Closed
GCM
202
Greenland Capital Management
New York
– -$1.23M -9,562 Closed
GCP
203
GSA Capital Partners
United Kingdom
– -$1.22M -9,548 Closed
DT
204
Diversified Trust
Tennessee
– -$1.2M -9,354 Closed
ET
205
Entropy Technologies
New York
– -$1.12M -8,722 Closed
William Blair Investment Management
206
William Blair Investment Management
Illinois
– -$1.1M -8,574 Closed
SO
207
STRS Ohio
Ohio
– -$1.06M -8,300 Closed
Mariner
208
Mariner
Kansas
– -$975K -7,605 Closed
BCM
209
BCK Capital Management
Connecticut
– -$974K -7,600 Closed
Fisher Asset Management
210
Fisher Asset Management
Washington
– -$956K -7,459 Closed
PCA
211
Pallas Capital Advisors
Massachusetts
– -$944K -7,361 Closed
CAG
212
Crestwood Advisors Group
Massachusetts
– -$917K -7,157 Closed
HC
213
Henshaw Capital
Massachusetts
– -$906K -7,066 Closed
GI
214
GAMCO Investors
Connecticut
– -$897K -7,000 Closed
Royal Bank of Canada
215
Royal Bank of Canada
Ontario, Canada
– -$861K -6,712 Closed
TRCT
216
Tower Research Capital (TRC)
New York
– -$837K -6,527 Closed
Public Employees Retirement Association of Colorado
217
Public Employees Retirement Association of Colorado
Colorado
– -$835K -6,512 Closed
AIP
218
Ameritas Investment Partners
Nebraska
– -$832K -6,492 Closed
Cetera Investment Advisers
219
Cetera Investment Advisers
Illinois
– -$819K -6,388 Closed
LPL Financial
220
LPL Financial
California
– -$803K -6,261 Closed
NMC
221
Nine Masts Capital
Hong Kong
– -$769K -6,000 Closed
QT
222
Quantbot Technologies
New York
– -$750K -5,848 Closed
VFA
223
Values First Advisors
Tennessee
– -$729K -5,685 Closed
AAM
224
Advisors Asset Management
Colorado
– -$699K -5,453 Closed
EGM
225
Engineers Gate Manager
New York
– -$692K -5,400 Closed
7 8
9
10 11

BPMC Hedge Fund Activity: Q3 2025 in Review

5 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.24B a quarter earlier.

Sellers outnumbered buyers: 344 funds closed out of BPMC and 0 opened new positions — a net loss of 344 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.

  • 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 354 in Q2 2025.
  • Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Blueprint Medicines positions in Q3 2025 and 344 closed out, a net change of -344 holders.
  • The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
  • The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.

Based on aggregated 13F filings for Q3 2025.